Bellevue Group AG trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 5.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,430,500 shares of the company’s stock after selling 153,050 shares during the period. Neurocrine […]
Sectoral Asset Management Inc. lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 10.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,445 shares of the company’s stock after buying an additional 410 shares during the period. Sectoral Asset Management […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective hoisted by UBS Group from $174.00 to $193.00 in a report issued on Tuesday morning, Benzinga reports. UBS Group currently has a buy rating on the stock. Several other equities research analysts have also recently issued reports on NBIX. Needham & Company LLC reaffirmed a […]
Wedbush reiterated their outperform rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a research note published on Wednesday morning, Benzinga reports. Wedbush currently has a $152.00 target price on the stock. NBIX has been the topic of a number of other research reports. Canaccord Genuity Group lifted their price target on shares […]
Primecap Management Co. CA raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 398,323 shares of the company’s stock after acquiring an additional 6,738 shares during the period. Primecap […]